Last reviewed 2026-04-22 · How we verify

Brepocitinib PO QD

Brepocitinib is a dual JAK1/TYK2 inhibitor that suppresses inflammatory signaling pathways to reduce immune-mediated tissue damage.

Brepocitinib is a dual JAK1/TYK2 inhibitor that suppresses inflammatory signaling pathways to reduce immune-mediated tissue damage. Used for Systemic lupus erythematosus (SLE), Ulcerative colitis.

At a glance

Mechanism of action

Brepocitinib selectively inhibits Janus kinase 1 (JAK1) and tyrosine kinase 2 (TYK2), which are key mediators of inflammatory cytokine signaling. By blocking these kinases, the drug reduces the activation and proliferation of immune cells involved in autoimmune and inflammatory diseases. This mechanism is particularly relevant for conditions driven by Type I and Type II interferon signaling.

Approved indications

• Systemic lupus erythematosus (SLE)
• Ulcerative colitis

Common side effects

• Infections
• Elevated lipids
• Liver enzyme elevation
• Headache

Key clinical trials

• A Study of Brepocitinib in Adults With Active, Non-Infectious, Non-Anterior Uveitis (PHASE3)
• A Study to Investigate the Efficacy and Safety of Brepocitinib in Adults With Dermatomyositis (PHASE3)
• A Study of Brepocitinib in Adults With Active Non-Infectious Non-Anterior Uveitis (PHASE2)
• A 12-Week Open-Label Study to Investigate the Efficacy and Safety of Brepocitinib in Adults With Skin-Predominant Dermatomyositis (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Brepocitinib PO QD CI brief — competitive landscape report
• Brepocitinib PO QD updates RSS · CI watch RSS
• Priovant Therapeutics, Inc. portfolio CI